Response  	Response  	 NN	B-NP
loss  	loss  	 NN	I-NP
and  	and  	 CC	O
development  	development  	 NN	O
of  	of  	 IN	O
neutralizing  	neutralizing  	 JJ	O
antibodies  	antibodies  	 NNS	B-NP
during  	during  	 IN	O
long-term  	long-term  	 JJ	O
treatment  	treatment  	 NN	O
with  	with  	 IN	O
romiplostim  	romiplostim  	 NN	B-NP
in  	in  	 IN	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
immune  	immune  	 JJ	O
thrombocytopenia 	thrombocytopenia 	 NN	B-NP
:  	:  	 :	O
a  	a  	 DT	O
case  	case  	 NN	B-NP
series  	series  	 NN	I-NP
Immune  	Immune  	 NNP	I-NP
thrombocytopenia  	thrombocytopenia  	 NNS	I-NP
( 	( 	 -LRB-	O
ITP 	ITP 	 NNP	B-NP
)  	)  	 -RRB-	O
is  	is  	 VBZ	O
an  	an  	 DT	O
autoimmune  	autoimmune  	 JJ	B-NP
disorder  	disorder  	 NN	I-NP
characterized  	characterized  	 VBN	O
by  	by  	 IN	O
low  	low  	 JJ	O
platelet  	platelet  	 NN	B-NP
counts  	counts  	 VBZ	O
resulting  	resulting  	 VBG	O
from  	from  	 IN	O
both  	both  	 DT	O
immune-mediated  	immune-mediated  	 JJ	O
platelet  	platelet  	 JJ	B-NP
destruction  	destruction  	 NN	I-NP
and  	and  	 CC	O
inappropriate  	inappropriate  	 JJ	O
bone  	bone  	 NN	O
marrow  	marrow  	 VBZ	O
platelet  	platelet  	 JJ	B-NP
production 	production 	 NN	I-NP
.  	.  	 .	O
Therefore 	Therefore 	 RB	O
,  	,  	 ,	O
in  	in  	 IN	O
ITP  	ITP  	 NNP	B-NP
patients  	patients  	 FW	I-NP
failing  	failing  	 FW	I-NP
immunosuppressants 	immunosuppressants 	 FW	I-NP
/ 	/ 	 FW	I-NP
splenectomy 	splenectomy 	 FW	I-NP
,  	,  	 ,	O
an  	an  	 DT	O
alternative  	alternative  	 JJ	O
approach  	approach  	 NN	O
is  	is  	 VBZ	O
to  	to  	 TO	O
enhance  	enhance  	 VB	O
platelet  	platelet  	 JJ	B-NP
production  	production  	 NN	I-NP
stimulating  	stimulating  	 VBG	I-NP
thrombopoiesis 	thrombopoiesis 	 NNS	I-NP
.  	.  	 .	O
Studies  	Studies  	 NNS	O
on  	on  	 IN	O
the  	the  	 DT	O
development  	development  	 NN	O
of  	of  	 IN	O
recombinant  	recombinant  	 JJ	O
thrombopoietins  	thrombopoietins  	 NNS	B-NP
( 	( 	 -LRB-	O
rhTPO 	rhTPO 	 NNP	B-NP
)  	)  	 -RRB-	O
were  	were  	 VBD	O
halted  	halted  	 VBN	O
since  	since  	 IN	O
a  	a  	 DT	O
minority  	minority  	 NN	O
of  	of  	 IN	O
patients  	patients  	 NNS	O
developed  	developed  	 VBD	O
an  	an  	 DT	O
autoantibody  	autoantibody  	 NN	B-NP
that  	that  	 IN	O
neutralized  	neutralized  	 JJ	O
pegylated  	pegylated  	 JJ	B-NP
rhTPO  	rhTPO  	 JJ	I-NP
and  	and  	 CC	O
also  	also  	 RB	O
cross-reacted  	cross-reacted  	 JJ	O
with  	with  	 IN	O
and  	and  	 CC	O
neutralized  	neutralized  	 JJ	O
endogenous  	endogenous  	 NNS	B-NP
TPO  	TPO  	 VBP	O
resulting  	resulting  	 VBG	O
in  	in  	 IN	O
thrombocytopenia 	thrombocytopenia 	 NN	B-NP
.  	.  	 .	O
Clinical  	Clinical  	 JJ	B-NP
use  	use  	 NN	I-NP
of  	of  	 IN	I-NP
romiplostim 	romiplostim 	 NN	I-NP
,  	,  	 ,	O
a  	a  	 DT	O
second-generation  	second-generation  	 JJ	B-NP
TPO-RAs 	TPO-RAs 	 NN	I-NP
,  	,  	 ,	O
has  	has  	 VBZ	O
shown  	shown  	 VBN	O
that  	that  	 IN	O
during  	during  	 IN	O
long-term  	long-term  	 JJ	O
treatment  	treatment  	 NN	O
it  	it  	 PRP	O
may  	may  	 MD	O
elicit  	elicit  	 VB	O
the  	the  	 DT	O
development  	development  	 NN	O
of  	of  	 IN	O
neutralizing  	neutralizing  	 JJ	O
antibodies  	antibodies  	 NNS	B-NP
to  	to  	 TO	O
this  	this  	 DT	O
agent  	agent  	 NN	B-NP
resulting  	resulting  	 VBG	O
in  	in  	 IN	O
acute  	acute  	 JJ	O
thrombocytopenia 	thrombocytopenia 	 NN	B-NP
.  	.  	 .	O
In  	In  	 IN	O
our  	our  	 PRP$	O
case  	case  	 NN	B-NP
series  	series  	 NN	I-NP
of  	of  	 IN	O
47  	47  	 CD	O
primary  	primary  	 JJ	B-NP
adult  	adult  	 NN	I-NP
ITP  	ITP  	 NN	I-NP
patients  	patients  	 NNS	I-NP
treated  	treated  	 VBN	O
with  	with  	 IN	O
romiplostim 	romiplostim 	 NN	B-NP
,  	,  	 ,	O
28 	28 	 CD	O
/ 	/ 	 CD	O
47  	47  	 CD	O
are  	are  	 VBP	O
evaluable  	evaluable  	 VBN	O
for  	for  	 IN	O
response  	response  	 NN	B-NP
loss 	loss 	 NN	I-NP
.  	.  	 .	O
Among  	Among  	 IN	O
these 	these 	 DT	O
,  	,  	 ,	O
we  	we  	 PRP	O
observed  	observed  	 VBD	O
8  	8  	 CD	O
patients  	patients  	 NNS	O
who  	who  	 WP	O
either  	either  	 RB	O
progressively  	progressively  	 RB	O
( 	( 	 -LRB-	O
3 	3 	 CD	O
/ 	/ 	 CD	O
8 	8 	 CD	O
)  	)  	 -RRB-	O
or  	or  	 CC	O
abruptly  	abruptly  	 RB	O
( 	( 	 -LRB-	O
5 	5 	 CD	O
/ 	/ 	 CD	O
8 	8 	 CD	O
)  	)  	 -RRB-	O
lost  	lost  	 VBD	O
response  	response  	 NN	O
which  	which  	 WDT	O
accounts  	accounts  	 VBZ	O
for  	for  	 IN	O
a  	a  	 DT	O
prevalence  	prevalence  	 NN	O
of  	of  	 IN	O
28,5 	28,5 	 CD	O
% 	% 	 NN	O
.  	.  	 .	O
Neutralizing  	Neutralizing  	 JJ	O
antibody  	antibody  	 NN	O
testing  	testing  	 NN	O
could  	could  	 MD	O
be  	be  	 VB	O
performed  	performed  	 VBN	O
in  	in  	 IN	O
4 	4 	 CD	O
/ 	/ 	 CD	O
8  	8  	 CD	O
patients  	patients  	 NNS	O
and  	and  	 CC	O
3 	3 	 CD	O
/ 	/ 	 CD	O
4  	4  	 CD	O
tested  	tested  	 VBN	O
positive 	positive 	 JJ	O
.  	.  	 .	O
These  	These  	 DT	O
antibodies  	antibodies  	 NNS	B-NP
did  	did  	 VBD	O
not  	not  	 RB	O
cross-react  	cross-react  	 JJ	O
with  	with  	 IN	O
endogenous  	endogenous  	 JJ	B-NP
TPO  	TPO  	 NNP	I-NP
and  	and  	 CC	O
re-testing  	re-testing  	 JJ	O
of  	of  	 IN	O
2  	2  	 CD	O
patients  	patients  	 NNS	O
at  	at  	 IN	O
9  	9  	 CD	O
and  	and  	 CC	O
7  	7  	 CD	O
months  	months  	 NNS	O
yielded  	yielded  	 VBD	O
a  	a  	 DT	O
negative  	negative  	 JJ	B-NP
result 	result 	 NN	I-NP
.  	.  	 .	O
At  	At  	 IN	O
follow-up 	follow-up 	 NNP	O
,  	,  	 ,	O
5 	5 	 CD	O
/ 	/ 	 CD	O
8  	8  	 CD	O
patients  	patients  	 NNS	O
-  	-  	 :	O
including  	including  	 VBG	O
the  	the  	 DT	O
3  	3  	 CD	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
neutralizing  	neutralizing  	 JJ	O
antibodies  	antibodies  	 NNS	B-NP
-  	-  	 :	O
went  	went  	 VBD	O
into  	into  	 IN	O
long-term  	long-term  	 JJ	O
complete  	complete  	 JJ	O
response  	response  	 NN	O
when  	when  	 WRB	O
switched  	switched  	 VBN	O
to  	to  	 TO	O
a  	a  	 DT	O
different  	different  	 JJ	O
therapy  	therapy  	 NN	O
while  	while  	 IN	O
3 	3 	 CD	O
/ 	/ 	 CD	O
8  	8  	 CD	O
patients  	patients  	 NNS	O
never  	never  	 RB	O
regained  	regained  	 VBD	O
a  	a  	 DT	O
response  	response  	 NN	O
on  	on  	 IN	O
subsequent  	subsequent  	 JJ	O
lines  	lines  	 NNS	O
of  	of  	 IN	O
therapy 	therapy 	 NN	O
.  	.  	 .	O
Response  	Response  	 NN	B-NP
loss  	loss  	 NN	I-NP
does 	does 	 VBZ	O
n't  	n't  	 RB	O
seem  	seem  	 VB	O
to  	to  	 TO	O
be  	be  	 VB	O
so  	so  	 RB	O
rare  	rare  	 JJ	O
an  	an  	 DT	O
event  	event  	 NN	O
during  	during  	 IN	O
romiplostim  	romiplostim  	 JJ	B-NP
administration  	administration  	 NN	I-NP
( 	( 	 -LRB-	O
28.5 	28.5 	 CD	O
%  	%  	 NN	O
in  	in  	 IN	O
our  	our  	 PRP$	O
series 	series 	 NN	O
)  	)  	 -RRB-	O
and  	and  	 CC	O
in  	in  	 IN	O
a  	a  	 DT	O
minority  	minority  	 NN	O
of  	of  	 IN	O
patients  	patients  	 NNS	O
it  	it  	 PRP	O
can  	can  	 MD	O
be  	be  	 VB	O
associated  	associated  	 VBN	O
with  	with  	 IN	O
development  	development  	 NN	O
of  	of  	 IN	O
drug  	drug  	 NN	B-NP
neutralizing  	neutralizing  	 NN	I-NP
antibodies 	antibodies 	 NNS	I-NP
.  	.  	 .	O
Although  	Although  	 IN	O
recognised  	recognised  	 NN	O
by  	by  	 IN	O
the  	the  	 DT	O
manufacturer  	manufacturer  	 NN	B-NP
as  	as  	 IN	O
a  	a  	 DT	O
possible  	possible  	 JJ	O
adverse  	adverse  	 JJ	O
event  	event  	 NN	O
ensuing  	ensuing  	 VBG	O
during  	during  	 IN	O
romiplostim  	romiplostim  	 JJ	B-NP
administration 	administration 	 NN	I-NP
,  	,  	 ,	O
development  	development  	 NN	O
of  	of  	 IN	O
neutralizing  	neutralizing  	 JJ	O
antibody  	antibody  	 NN	B-NP
in  	in  	 IN	O
everyday  	everyday  	 JJ	O
clinical  	clinical  	 JJ	B-NP
practice  	practice  	 NN	I-NP
has  	has  	 VBZ	O
so  	so  	 RB	O
far  	far  	 RB	O
not  	not  	 RB	O
been  	been  	 VBN	O
specifically  	specifically  	 RB	O
addressed  	addressed  	 VBN	O
in  	in  	 IN	O
reports  	reports  	 NNS	O
on  	on  	 IN	O
romiplostim  	romiplostim  	 JJ	B-NP
use  	use  	 NN	I-NP
outside  	outside  	 IN	O
controlled  	controlled  	 JJ	O
studies 	studies 	 NNS	O
.  	.  	 .	O
Unfortunately 	Unfortunately 	 RB	O
,  	,  	 ,	O
testing  	testing  	 VBG	O
for  	for  	 IN	O
these  	these  	 DT	O
antibodies  	antibodies  	 NN	B-NP
requires  	requires  	 VBZ	O
adhesion  	adhesion  	 VBN	B-NP
to  	to  	 TO	O
strict  	strict  	 JJ	O
procedures  	procedures  	 NNS	O
which  	which  	 WDT	O
is  	is  	 VBZ	O
not  	not  	 RB	O
easily  	easily  	 RB	O
accomplished  	accomplished  	 VBN	O
in  	in  	 IN	O
everyday  	everyday  	 JJ	O
clinical  	clinical  	 JJ	B-NP
practice 	practice 	 NN	I-NP
.  	.  	 .	O
This  	This  	 DT	O
complexity  	complexity  	 NN	O
represents  	represents  	 VBZ	O
a  	a  	 DT	O
significant  	significant  	 JJ	O
draw  	draw  	 NN	O
back  	back  	 RB	O
in  	in  	 IN	O
extending  	extending  	 VBG	O
antibody  	antibody  	 NN	O
testing  	testing  	 NN	O
to  	to  	 TO	O
all  	all  	 DT	O
patients  	patients  	 NNS	O
who  	who  	 WP	O
lose  	lose  	 VBP	O
response  	response  	 NN	O
to  	to  	 TO	O
romiplostim  	romiplostim  	 VB	O
This  	This  	 DT	O
article  	article  	 NN	O
is  	is  	 VBZ	O
protected  	protected  	 VBN	O
by  	by  	 IN	O
copyright 	copyright 	 NN	O
.  	.  	 .	O
All  	All  	 DT	O
rights  	rights  	 NNS	O
reserved 	reserved 	 VBN	O
.  	.  	 .	O
